Recent Finacing
Recent Raise
Eleventa is a Russian biotech developing OC459, an oral once-daily small-molecule CRTH2 antagonist for moderate-to-severe asthma and allergic respiratory diseases, partnered with Oxagen and preparing pivotal Russian trials.
Focus Areas
Recent Investors
Funding round
Investor